SIMCERE PHARMA (02096) saw its shares increase by more than 3%. At the time of writing, the stock was up 2.69%, trading at HK$12.61, with a turnover of HK$22.02 million. The movement follows a recent announcement by the company regarding its subsidiary's overseas option agreement with an affiliate of AbbVie Inc. for the investigational new drug candidate SIM0500. Under the agreement terms, the group will receive an upfront payment, along with potential option exercise fees and milestone payments totaling up to $1.055 billion, in addition to tiered royalties on net sales. Huatai Securities noted that SIMCERE PHARMA's core product SIM0500 has received a $40 million milestone payment from AbbVie. The BCMA/GPRC5D/CD3 trispecific T-cell engager has been granted Fast Track designation by the FDA, with Phase I clinical data expected to be read out within the year for proof-of-concept validation. The brokerage believes that the company's innovative R&D system and platform technology capabilities continue to be validated, having secured multiple overseas licensing deals valued in the billion-dollar range. Preclinical studies for SIM0500 have demonstrated significantly superior anti-tumor activity compared to bispecific T-cell engagers, positioning it as a global leader among competitors targeting the same combination.